Allos Therapeutics to Present at SG Cowen's Healthcare Conference
11 3월 2005 - 8:00PM
PR Newswire (US)
Allos Therapeutics to Present at SG Cowen's Healthcare Conference
WESTMINSTER, Colo., March 11 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) today announced that the Company
will participate in SG Cowen's 2005 Healthcare Conference, to be
held March 14 - 17 in Boston, MA. Michael E. Hart, the Company's
President and Chief Executive Officer will give a 40-minute
corporate overview on Wednesday, March 16 at 2:20 PM ET. The
presentation will be webcast live and may be accessed by visiting
the Allos website at http://www.allos.com/. A replay of the webcast
will also be available on the company's website until Friday, April
15, 2005. About Allos Therapeutics, Inc. Allos Therapeutics, Inc.
is a biopharmaceutical company focused on developing and
commercializing innovative drugs for improving cancer treatments.
The company's lead clinical candidate, EFAPROXYN(TM) (efaproxiral),
is a synthetic small molecule that has the potential to sensitize
hypoxic (oxygen deprived) tumor tissues and enhance the efficacy of
standard radiation therapy. In addition, Allos is developing PDX
(pralatrexate), a novel small molecule cytotoxic injectable
antifolate (DHFR inhibitor) intended to treat non-small cell lung
cancer and non-Hodgkin's lymphoma, as well as RH1, a targeted
cytotoxic prodrug under investigation in patients with advanced
solid tumors. For more information, please visit the company's web
site at: http://www.allos.com/. Safe Harbor Statement This press
release and the anticipated presentation contain forward- looking
statements that involve significant risks and uncertainties,
including those discussed in this release, those to be discussed in
the presentation and others that can be found in the "Risk Factors"
section of the Company's Form 10-K/A for the year ended December
31, 2003 and in the Company's periodic reports on Form 10-Q and
Form 8-K. The Company does not undertake any obligation to update
any forward-looking statements contained in this document or the
anticipated presentation as a result of new information, future
events or otherwise. The Company cautions investors not to place
undue reliance on the forward-looking statements contained in this
press release or the presentation. No forward-looking statement can
be guaranteed and actual events and results may differ materially
from those projected. DATASOURCE: Allos Therapeutics, Inc. CONTACT:
Jennifer Neiman, Manager, Corporate Communications of Allos
Therapeutics, +1-720-540-5227, Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Allos Therapeutics (MM) News Articles